11,490 Danaher Corporation $DHR Shares Acquired by Ethic Inc.

Ethic Inc. boosted its holdings in shares of Danaher Corporation (NYSE:DHR) by 15.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 84,419 shares of the conglomerate’s stock after acquiring an additional 11,490 shares during the period. Ethic Inc.’s holdings in Danaher were worth $18,703,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Danaher in the second quarter worth about $10,492,520,000. Wellington Management Group LLP raised its position in shares of Danaher by 10.4% during the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after purchasing an additional 1,542,310 shares during the period. Jupiter Topco LLC bought a new position in shares of Danaher during the 2nd quarter valued at about $1,456,317,000. Generation Investment Management LLP bought a new position in shares of Danaher during the 2nd quarter valued at about $1,287,949,000. Finally, Bank of America Corp DE acquired a new position in shares of Danaher in the 2nd quarter valued at approximately $993,846,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Up 1.8%

NYSE:DHR opened at $230.34 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.29 and a current ratio of 1.63. The company has a market cap of $162.05 billion, a PE ratio of 37.70, a PEG ratio of 2.89 and a beta of 0.76. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The stock has a 50-day simple moving average of $220.27 and a 200 day simple moving average of $201.60.

Danaher (NYSE:DHR) last released its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating the consensus estimate of $1.92 by $0.19. The firm had revenue of $6.55 billion for the quarter, compared to analysts’ expectations of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.89 EPS. On average, sell-side analysts expect that Danaher Corporation will post 8.59 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were issued a $0.40 dividend. The ex-dividend date was Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 26.19%.

Insider Activity

In other news, CAO Christopher Bouda sold 7,598 shares of the business’s stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $234.56, for a total value of $1,782,186.88. Following the sale, the chief accounting officer owned 9,107 shares of the company’s stock, valued at $2,136,137.92. The trade was a 45.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.80% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Robert W. Baird increased their target price on Danaher from $246.00 to $254.00 and gave the stock an “outperform” rating in a research note on Thursday, October 22nd. TD Cowen lifted their price target on shares of Danaher from $255.00 to $270.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Royal Bank Of Canada increased their price objective on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Citigroup raised their price objective on shares of Danaher from $230.00 to $270.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $275.00 price objective on shares of Danaher in a research report on Thursday, October 22nd. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $242.91.

Danaher Profile

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing.

The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.